Literature DB >> 29246723

Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.

Jason Schapansky1, Saurabh Khasnavis1, Mark P DeAndrade1, Jonathan D Nardozzi1, Samuel R Falkson1, Justin D Boyd1, John B Sanderson1, Tim Bartels1, Heather L Melrose2, Matthew J LaVoie3.   

Abstract

Missense mutations in the multi-domain kinase LRRK2 cause late onset familial Parkinson's disease. They most commonly with classic proteinopathy in the form of Lewy bodies and Lewy neurites comprised of insoluble α-synuclein, but in rare cases can also manifest tauopathy. The normal function of LRRK2 has remained elusive, as have the cellular consequences of its mutation. Data from LRRK2 null model organisms and LRRK2-inhibitor treated animals support a physiological role for LRRK2 in regulating lysosome function. Since idiopathic and LRRK2-linked PD are associated with the intraneuronal accumulation of protein aggregates, a series of critical questions emerge. First, how do pathogenic mutations that increase LRRK2 kinase activity affect lysosome biology in neurons? Second, are mutation-induced changes in lysosome function sufficient to alter the metabolism of α-synuclein? Lastly, are changes caused by pathogenic mutation sensitive to reversal with LRRK2 kinase inhibitors? Here, we report that mutation of LRRK2 induces modest but significant changes in lysosomal morphology and acidification, and decreased basal autophagic flux when compared to WT neurons. These changes were associated with an accumulation of detergent-insoluble α-synuclein and increased neuronal release of α-synuclein and were reversed by pharmacologic inhibition of LRRK2 kinase activity. These data demonstrate a critical and disease-relevant influence of native neuronal LRRK2 kinase activity on lysosome function and α-synuclein homeostasis. Furthermore, they also suggest that lysosome dysfunction, altered neuronal α-synuclein metabolism, and the insidious accumulation of aggregated protein over decades may contribute to pathogenesis in this late-onset form of familial PD.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  LRRK2; Lysosome; Parkinson's disease; Tau; Tau phosphorylation; α-Synuclein

Mesh:

Substances:

Year:  2017        PMID: 29246723      PMCID: PMC5803451          DOI: 10.1016/j.nbd.2017.12.005

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  77 in total

1.  Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway.

Authors:  Jochen Klucken; Anne-Maria Poehler; Darius Ebrahimi-Fakhari; Jacqueline Schneider; Silke Nuber; Edward Rockenstein; Ursula Schlötzer-Schrehardt; Bradley T Hyman; Pamela J McLean; Eliezer Masliah; Juergen Winkler
Journal:  Autophagy       Date:  2012-05-01       Impact factor: 16.016

2.  LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis.

Authors:  Samer Matta; Kristof Van Kolen; Raquel da Cunha; Geert van den Bogaart; Wim Mandemakers; Katarzyna Miskiewicz; Pieter-Jan De Bock; Vanessa A Morais; Sven Vilain; Dominik Haddad; Lore Delbroek; Jef Swerts; Lucía Chávez-Gutiérrez; Giovanni Esposito; Guy Daneels; Eric Karran; Matthew Holt; Kris Gevaert; Diederik W Moechars; Bart De Strooper; Patrik Verstreken
Journal:  Neuron       Date:  2012-09-20       Impact factor: 17.173

3.  LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism.

Authors:  Amaia M Arranz; Lore Delbroek; Kristof Van Kolen; Marco R Guimarães; Wim Mandemakers; Guy Daneels; Samer Matta; Sara Calafate; Hamdy Shaban; Pieter Baatsen; Pieter-Jan De Bock; Kris Gevaert; Pieter Vanden Berghe; Patrik Verstreken; Bart De Strooper; Diederik Moechars
Journal:  J Cell Sci       Date:  2015-02-01       Impact factor: 5.285

4.  Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.

Authors:  Omar M A El-Agnaf; Sultan A Salem; Katerina E Paleologou; Leanne J Cooper; Nigel J Fullwood; Mark J Gibson; Martin D Curran; Jennifer A Court; David M A Mann; Shu-ichi Ikeda; Mark R Cookson; John Hardy; David Allsop
Journal:  FASEB J       Date:  2003-08-15       Impact factor: 5.191

5.  Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.

Authors:  Edward D Plowey; Salvatore J Cherra; Yong-Jian Liu; Charleen T Chu
Journal:  J Neurochem       Date:  2008-01-07       Impact factor: 5.372

6.  Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Authors:  Byoung Dae Lee; Joo-Ho Shin; Jackalina VanKampen; Leonard Petrucelli; Andrew B West; Han Seok Ko; Yun-Il Lee; Kathleen A Maguire-Zeiss; William J Bowers; Howard J Federoff; Valina L Dawson; Ted M Dawson
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

7.  α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation.

Authors:  Tim Bartels; Joanna G Choi; Dennis J Selkoe
Journal:  Nature       Date:  2011-08-14       Impact factor: 49.962

8.  LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice.

Authors:  Martin C Herzig; Carine Kolly; Elke Persohn; Diethilde Theil; Tatjana Schweizer; Thomas Hafner; Christine Stemmelen; Thomas J Troxler; Peter Schmid; Simone Danner; Christian R Schnell; Matthias Mueller; Bernd Kinzel; Armelle Grevot; Federico Bolognani; Martina Stirn; Rainer R Kuhn; Klemens Kaupmann; P Herman van der Putten; Giorgio Rovelli; Derya R Shimshek
Journal:  Hum Mol Genet       Date:  2011-08-09       Impact factor: 6.150

9.  LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6.

Authors:  Daniel C Berwick; Kirsten Harvey
Journal:  Hum Mol Genet       Date:  2012-08-16       Impact factor: 6.150

10.  Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo.

Authors:  Valerie Cullen; Maria Lindfors; Juliana Ng; Anders Paetau; Erika Swinton; Piotr Kolodziej; Heather Boston; Paul Saftig; John Woulfe; Mel B Feany; Liisa Myllykangas; Michael G Schlossmacher; Jaana Tyynelä
Journal:  Mol Brain       Date:  2009-02-09       Impact factor: 4.041

View more
  46 in total

1.  Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions.

Authors:  Julia Obergasteiger; Giulia Frapporti; Giulia Lamonaca; Sara Pizzi; Anne Picard; Alexandros A Lavdas; Francesca Pischedda; Giovanni Piccoli; Sabine Hilfiker; Evy Lobbestael; Veerle Baekelandt; Andrew A Hicks; Corrado Corti; Peter P Pramstaller; Mattia Volta
Journal:  Cell Death Discov       Date:  2020-06-08

Review 2.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

Review 3.  Role of the endolysosomal system in Parkinson's disease.

Authors:  D J Vidyadhara; John E Lee; Sreeganga S Chandra
Journal:  J Neurochem       Date:  2019-07-31       Impact factor: 5.372

4.  Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia.

Authors:  Adamantios Mamais; Jillian H Kluss; Luis Bonet-Ponce; Natalie Landeck; Rebekah G Langston; Nathan Smith; Alexandra Beilina; Alice Kaganovich; Manik C Ghosh; Laura Pellegrini; Ravindran Kumaran; Ioannis Papazoglou; George R Heaton; Rina Bandopadhyay; Nunziata Maio; Changyoun Kim; Matthew J LaVoie; David C Gershlick; Mark R Cookson
Journal:  PLoS Biol       Date:  2021-12-16       Impact factor: 8.029

5.  Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition.

Authors:  Anwesha Sanyal; Mark P DeAndrade; Hailey S Novis; Steven Lin; Jianjun Chang; Nathalie Lengacher; Julianna J Tomlinson; Malú G Tansey; Matthew J LaVoie
Journal:  Mov Disord       Date:  2020-02-08       Impact factor: 10.338

Review 6.  Parkinson's disease and mitophagy: an emerging role for LRRK2.

Authors:  Francois Singh; Ian G Ganley
Journal:  Biochem Soc Trans       Date:  2021-04-30       Impact factor: 5.407

Review 7.  Neuronal autophagy and mitophagy in Parkinson's disease.

Authors:  Britney N Lizama; Charleen T Chu
Journal:  Mol Aspects Med       Date:  2021-06-12

8.  Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor.

Authors:  Eli J Cornblath; Howard L Li; Lakshmi Changolkar; Bin Zhang; Hannah J Brown; Ronald J Gathagan; Modupe F Olufemi; John Q Trojanowski; Danielle S Bassett; Virginia M Y Lee; Michael X Henderson
Journal:  Sci Adv       Date:  2021-06-09       Impact factor: 14.136

9.  Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.

Authors:  Linn Streubel-Gallasch; Veronica Giusti; Michele Sandre; Isabella Tessari; Nicoletta Plotegher; Elena Giusto; Anna Masato; Ludovica Iovino; Ilaria Battisti; Giorgio Arrigoni; Derya Shimshek; Elisa Greggio; Marie-Eve Tremblay; Luigi Bubacco; Anna Erlandsson; Laura Civiero
Journal:  Mol Neurobiol       Date:  2021-02-24       Impact factor: 5.590

10.  Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease.

Authors:  Barbara Calamini; Nathalie Geyer; Nathalie Huss-Braun; Annie Bernhardt; Véronique Harsany; Pierrick Rival; May Cindhuchao; Dietmar Hoffmann; Sabine Gratzer
Journal:  Dis Model Mech       Date:  2021-06-11       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.